UNSPSC 51391617: Prenylamine lactate

This classification denotes an adrenergic agent C24H27N.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J3J6SXI7V, chemically known as benzenepropanamine, n-(1-methyl-2-phenylethyl)-.gamma.-phenyl-, 2-hydroxypropanoate, but more generally known as prenylamine lactate, which bears US NIH Compound Identifier 65557. European Medicines Agency schedules Prenylamine lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04033MIG.

Most nations, for tariff and trade purposes, schedule prenylamine lactate under HS 29214980 and SITC 51454. As of Q4 2014, PRENYLAMINE LACTATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCCC1)NCCC(C2CCCCC2)C3CCCCC3.CC(C(=O)O)O.

UNSPSC 51391617 Prenylamine lactate is a Commodity code that in practice captures pharmaceutical products and related health-system procurement, though the recent state and local opportunities tagged under it show a significant mismatch with the code's nominal scope. Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB (Solicitation IFB60459723LAS, due July 26, 2023), while the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer pharmacy prescription programs (RFI HHS0017013, posted April 3, 2026). These opportunities reflect broader pharmaceutical supply-chain and prescription-management initiatives rather than procurement specific to prenylamine lactate itself. State and local health departments, county health agencies, and state HHS commissions are the issuing bodies engaging under or near this code, pursuing capabilities in drug acquisition, pharmacy benefit management, and emergency-response pharmaceuticals.

The geographic spread includes Florida and Texas in the most recent activity. The Seminole County procurement demonstrates a near-term, transactional opportunity—annual acquisition of 1,900 units of naloxone and 800 deactivation systems with quarterly deliveries, E-Verify and drug-free workplace compliance required, and a two-year initial term with one-year renewal option. The Texas RFI represents longer-range strategic procurement planning, exploring vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels. Neither opportunity specifies set-aside designations. The code shows limited and scattered recent activity; business development professionals should verify whether prenylamine lactate itself drives material procurement volume or whether the code tag reflects broader pharmaceutical categorization by state procurement offices.